ALK and non-small cell lung carcinoma: In addition, the use of ALK-TKIs in advanced NSCLC patients significantly increased the risk of developing grade 3–4 of ALT increase with RR of 8.92 (95% CI, 4.67–17.0; p < 0.001, Figure 3B).